Parse Biosciences and Graph Therapeutics announced a strategic partnership to create a large‑scale, functional immune perturbation atlas combining Graph’s patient‑derived disease models and active learning platform with Parse’s GigaLab/Evercode single‑cell technology. The initiative aims to profile hundreds of millions of cells under systematic perturbations to accelerate target discovery and predict clinical outcomes. The collaboration seeks to close the gap between in vitro predictions and patient responses, enabling AI‑first discovery workflows that can prioritize robust candidates and reduce late‑stage failures. Graph’s CEO Gregory Vladimer highlighted the project’s potential to transform immune‑disease drug discovery by providing high‑context biological datasets at scale.